title: Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development.
authors.affiliation: Institute of Drug Development, Division of Cancer Research and Therapy Center, University of Texas Health Science Center, San Antonio, Texas, USA.
authors.forename: Devalingam
authors.initials: D
authors.lastname: Mahalingam
authors.forename: Alain
authors.initials: A
authors.lastname: Mita
authors.forename: Monica M
authors.initials: MM
authors.lastname: Mita
authors.forename: Steffan T
authors.initials: ST
authors.lastname: Nawrocki
authors.forename: Francis J
authors.initials: FJ
authors.lastname: Giles
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001499:Bayes Theorem; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D016503:Drug Delivery Systems / Q000639:trends*; D006655:Histone Deacetylases / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010818:Practice Patterns, Physicians' / Q000639:trends; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D018714:Radiotherapy, Adjuvant; D017526:Receptor, IGF Type 1 / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D011505:Protein-Tyrosine Kinases; D017526:Receptor, IGF Type 1; D006655:Histone Deacetylases